...Okay. We are live. Well, let's kick things off. This is David Amsellem from the Piper Sandler biopharma research team. We're delighted to have Neurocrine here. We have Matt Abernethy, CFO. We have Eric Benevich, Chief Commercial Officer. We have Todd Tushla, Director of Investor Relations. Thanks, gentlemen, for joining us. So it's been quite a year. So I would love to turn it over to Matt for just a few opening remarks on, I guess, a reflection on what's been to say the least, an interesting year, both for Neurocrine and for the biotech space, we're at large. Matthew Abernethy ...